1
|
Chen Z, Huang Q, Song Y, Feng X, Zeng L, Liu Z, Hu X, Tao C, Wang L, Qi Y, Song H. Cubosomes-assisted transdermal delivery of doxorubicin and indocyanine green for chemo-photothermal combination therapy of melanoma. Biomed Pharmacother 2023; 166:115316. [PMID: 37572638 DOI: 10.1016/j.biopha.2023.115316] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Revised: 08/07/2023] [Accepted: 08/08/2023] [Indexed: 08/14/2023] Open
Abstract
Melanoma is a highly aggressive form of skin cancer with limited therapeutic options. Chemo-photothermal combination therapy has demonstrated potential for effectively treating melanoma, and transdermal administration is considered the optimal route for treating skin diseases due to its ability to bypass first-pass metabolism and enhance drug concentration. However, the stratum corneum presents a formidable challenge as a significant barrier to drug penetration in transdermal drug delivery. Lipid-nanocarriers, particularly cubosomes, have been demonstrated to possess significant potential in augmenting drug permeation across the stratum corneum. Herein, cubosomes co-loaded with doxorubicin (DOX, a chemotherapeutic drug) and indocyanine green (ICG, a photothermal agent) (DOX-ICG-cubo) transdermal drug delivery system was developed to enhance the therapeutic efficiency of melanoma by improving drug permeation. The DOX-ICG-cubo showed high encapsulation efficiency of both DOX and ICG, and exhibited good stability under physiological conditions. In addition, the unique cubic structure of the DOX-ICG-cubo was confirmed through transmission electron microscopy (TEM) images, polarizing microscopy, and small angle X-ray scattering (SAXS). The DOX-ICG-cubo presented high photothermal conversion efficiency, as well as pH and thermo-responsive DOX release. Notably, the DOX-ICG-cubo exhibited enhanced drug permeation efficiency, good biocompatibility, and improved in vivo anti-melanoma efficacy through the synergistic effects of chemo-photothermal therapy. In conclusion, DOX-ICG-cubo presented a promising strategy for melanoma treatment.
Collapse
Affiliation(s)
- Zhenzhen Chen
- Department of Pharmacy, Fuzong Clinical Medical College of Fujian Medical University, Fuzhou 350025, PR China; Department of Pharmacy, 900TH Hospital of Joint Logistics Support Force, People's Liberation Army (PLA), Fuzhou 350025, PR China
| | - Qinbiao Huang
- Department of Pharmacy, 900TH Hospital of Joint Logistics Support Force, People's Liberation Army (PLA), Fuzhou 350025, PR China
| | - Yutong Song
- The First School of Clinical Medicine, Nanjing Medical University, Nanjing 210029, PR China
| | - Xianquan Feng
- Department of Pharmacy, 900TH Hospital of Joint Logistics Support Force, People's Liberation Army (PLA), Fuzhou 350025, PR China
| | - Lingjun Zeng
- Department of Pharmacy, 900TH Hospital of Joint Logistics Support Force, People's Liberation Army (PLA), Fuzhou 350025, PR China
| | - Zhihong Liu
- Department of Pharmacy, 900TH Hospital of Joint Logistics Support Force, People's Liberation Army (PLA), Fuzhou 350025, PR China
| | - Xiaomu Hu
- Department of Pharmacy, 900TH Hospital of Joint Logistics Support Force, People's Liberation Army (PLA), Fuzhou 350025, PR China
| | - Chun Tao
- Department of Pharmacy, 900TH Hospital of Joint Logistics Support Force, People's Liberation Army (PLA), Fuzhou 350025, PR China
| | - Lie Wang
- Department of General Surgery, 900TH Hospital of Joint Logistics Support Force, People's Liberation Army (PLA), Fuzhou 350025, PR China
| | - Yafeng Qi
- Department of General Surgery, 900TH Hospital of Joint Logistics Support Force, People's Liberation Army (PLA), Fuzhou 350025, PR China.
| | - Hongtao Song
- Department of Pharmacy, 900TH Hospital of Joint Logistics Support Force, People's Liberation Army (PLA), Fuzhou 350025, PR China.
| |
Collapse
|
2
|
Pushpa Ragini S, White J, Kirby N, Banerjee R, Reddy Bathula S, Drummond CJ, Conn CE. Novel bioactive cationic cubosomes enhance the cytotoxic effect of paclitaxel against a paclitaxel resistant prostate cancer cell-line. J Colloid Interface Sci 2023; 649:966-976. [PMID: 37392686 DOI: 10.1016/j.jcis.2023.06.122] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2023] [Revised: 06/05/2023] [Accepted: 06/17/2023] [Indexed: 07/03/2023]
Abstract
Hypothesis The study aimed to use molecular hybridization of a cationic lipid with a known pharmacophore to produce a bifunctional lipid having a cationic charge to enhance fusion with the cancer cell surface and biological activity via the pharmacophoric head group. Experiments The novel cationic lipid DMP12 [N-(2-(3-(3,4-dimethoxyphenyl) propanamido) ethyl)-N-dodecyl-N-methyldodecan-1-aminium iodide] was synthesised by conjugating 3-(3,4-dimethoxyphenyl) propanoic acid (or 3,4-dimethoxyhydrocinnamic acid) to twin 12 carbon chains bearing a quaternary ammonium group [N-(2-aminoethyl)-N-dodecyl-N-methyldodecan-1-aminium iodide]. The physicochemical and biological properties of DMP12 were investigated. Cubosome particles consisting of monoolein (MO) doped with DMP12 and paclitaxel were characterized using Small-angle X-ray Scattering (SAXS), Dynamic Light Scattering (DLS), and Cryo-Transmission Electron Microscopy (Cryo-TEM). Combination therapy using these cubosomes was assessed in vitro against the gastric (AGS) and prostate (DU-145 and PC-3) cancer cell lines using cytotoxicity assay. Findings Monoolein (MO) cubosomes doped with DMP12 were observed to be toxic against the AGS and DU-145 cell-lines at higher cubosome concentrations (≥100 µg/ml) but had limited activity against the PC-3 cell-line. However, combination therapy consisting of 5 mol% DMP12 and 0.5 mol% paclitaxel (PTX) significantly increased the cytotoxicity against the PC-3 cell-line which was resistant to either DMP12 or PTX individually. The results demonstrate that DMP12 has a prospective role as a bioactive excipient in cancer therapy.
Collapse
Affiliation(s)
- S Pushpa Ragini
- Department of Oils, lipids science and technology, CSIR-Indian Institute of Chemical Technology, Hyderabad 500 007, India; Academy of Scientific and Innovation Research (AcSIR), Ghaziabad, 201002, India; Department of Organic Synthesis and Process Chemistry, CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad-500007, India; School of Science, College of Science, Engineering and Health, RMIT University, Melbourne 3000, Victoria, Australia
| | - Jacinta White
- CSIRO Manufacturing, Bayview Avenue, Clayton, VIC 3168, Australia
| | - Nigel Kirby
- Australian Synchrotron, 800 Blackburn Rd, Clayton, VIC 3168, Australia
| | - Rajkumar Banerjee
- Department of Oils, lipids science and technology, CSIR-Indian Institute of Chemical Technology, Hyderabad 500 007, India; Academy of Scientific and Innovation Research (AcSIR), Ghaziabad, 201002, India
| | - Surendar Reddy Bathula
- Academy of Scientific and Innovation Research (AcSIR), Ghaziabad, 201002, India; Department of Organic Synthesis and Process Chemistry, CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad-500007, India
| | - Calum J Drummond
- School of Science, College of Science, Engineering and Health, RMIT University, Melbourne 3000, Victoria, Australia
| | - Charlotte E Conn
- School of Science, College of Science, Engineering and Health, RMIT University, Melbourne 3000, Victoria, Australia.
| |
Collapse
|
3
|
Sarkar S, Dyett B, Lakic B, Ball AS, Yeo LY, White JF, Soni S, Drummond CJ, Conn CE. Cubosome Lipid Nanocarriers As a Drug Delivery Vehicle for Intracellular Mycobacterium tuberculosis Infections. ACS APPLIED MATERIALS & INTERFACES 2023; 15:21819-21829. [PMID: 37018059 DOI: 10.1021/acsami.3c00101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Mycobacterium tuberculosis (MTB) causes the infectious disease tuberculosis (TB), responsible for more deaths than any other single infectious disease in history. Intracellular MTB are slow growing and difficult to target with traditional antitubercular drugs, leading to the emergence of multidrug resistance in TB infection, which is a major global public health issue. Recent advances in innovative lipid nanotechnologies for drug delivery have demonstrated promising outcomes for chronic infectious diseases but have not yet been tested as potential delivery systems for intracellular infections such as TB. The current study evaluates the potential of monoolein (MO)-based cationic cubosomes for the encapsulation and delivery of the first line antitubercular drug rifampicin (RIF) against an MTB-H37Ra in vitro culture model. In particular, we show that the use of cationic cubosomes as delivery vehicles reduced the minimum inhibitory concentration (MIC) of RIF by 2-fold against actively replicating MTB-H37Ra (compared to that of the free drug) and also shortened the lifecycle duration of axenic MTB-H37Ra from 5 to 3 days. The cubosome-mediated delivery was also found to be effective against intracellular MTB-H37Ra within THP-1 human macrophages, with a 2.8 log reduction in viability of the bacilli after 6 days incubation at the MIC. The killing time was also reduced from 8 to 6 days without distressing the host macrophages. Mechanistic studies on the uptake of RIF-loaded cationic cubosomes using total internal reflection fluorescence microscopy (TIRFM) demonstrated the capacity of these lipid particles to effectively target intracellular bacteria. Overall, these results demonstrate that cationic cubosomes are a potent delivery system for the antitubercular drug RIF for therapeutic management of TB.
Collapse
Affiliation(s)
- Sampa Sarkar
- School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia
| | - Brendan Dyett
- School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia
| | - Biserka Lakic
- School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia
| | - Andrew S Ball
- School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia
| | - Leslie Y Yeo
- School of Engineering, STEM College, RMIT University, Melbourne, Victoria 3001, Australia
| | - Jacinta F White
- The Commonwealth Scientific and Industrial Research Organisation, Manufacturing, Clayton, Victoria 3169, Australia
| | - Sarvesh Soni
- School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia
| | - Calum J Drummond
- School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia
| | - Charlotte E Conn
- School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia
| |
Collapse
|
4
|
Yu H, Dyett BP, Zhai J, Strachan JB, Drummond CJ, Conn CE. Formation of particulate lipid lyotropic liquid crystalline nanocarriers using a microfluidic platform. J Colloid Interface Sci 2023; 634:279-289. [PMID: 36542965 DOI: 10.1016/j.jcis.2022.12.028] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Revised: 11/30/2022] [Accepted: 12/06/2022] [Indexed: 12/13/2022]
Abstract
HYPOTHESIS Non-lamellar lyotropic liquid crystal nanoparticles (LLCNPs) are gaining significant interest in the fields of drug delivery and nanomedicine. Traditional, top-down formulation strategies for LLCNPs are typically low-throughput, can lack controllability and reproducibility in the particle size distribution, and may be unsuitable for loading more fragile therapeutics. The development of a controllable, reproducible, scalable, and high-throughput strategy is urgently needed. EXPERIMENTS Monoolein (MO)-based LLCNPs with various stabilizers (F127, F108, and Tween 80) and phytantriol (PT)-F127 cubosomes were produced at various flow conditions via a bottom-up method using a microfluidic platform. FINDINGS This simple enabling strategy was used to formulate LLCNPs with lower polydispersity compared to the traditional top-down homogenization method. Significantly, particle size could be quantitatively controlled by varying the overall flow-rate; a scaling law was identified between nanoparticle mean size and the total flow rate (Q) of meansize∼Q-0.15 for MO cubosomes and meansize∼Q-0.19 for PT cubosomes (at a fixed flow rate ratio). Effective size control was achieved for a range of cubosome formulations involving different lipids and stabilizers. The formulation of stable, drug-loaded cubosomes with high encapsulation efficiency using this method was exemplified using calcein as a model drug. This work will further promote the utilisation of LLCNPs in nanomedicine and facilitate their clinical translation.
Collapse
Affiliation(s)
- Haitao Yu
- School of Science, STEM College, RMIT University, Victoria, Australia.
| | - Brendan P Dyett
- School of Science, STEM College, RMIT University, Victoria, Australia
| | - Jiali Zhai
- School of Science, STEM College, RMIT University, Victoria, Australia
| | - Jamie B Strachan
- School of Science, STEM College, RMIT University, Victoria, Australia
| | - Calum J Drummond
- School of Science, STEM College, RMIT University, Victoria, Australia.
| | - Charlotte E Conn
- School of Science, STEM College, RMIT University, Victoria, Australia.
| |
Collapse
|
5
|
Yu H, Palazzolo JS, Ju Y, Niego B, Pan S, Hagemeyer CE, Caruso F. Polyphenol-Functionalized Cubosomes as Thrombolytic Drug Carriers. Adv Healthc Mater 2022; 11:e2201151. [PMID: 36037807 DOI: 10.1002/adhm.202201151] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2022] [Revised: 08/03/2022] [Indexed: 01/28/2023]
Abstract
The safe administration of thrombolytic agents is a challenge for the treatment of acute thrombosis. Lipid-based nanoparticle drug delivery technologies present opportunities to overcome the existing clinical limitations and deliver thrombolytic therapy with enhanced therapeutic outcomes and safety. Herein, lipid cubosomes are examined as nanocarriers for the encapsulation of thrombolytic drugs. The lipid cubosomes are loaded with the thrombolytic drug urokinase-type plasminogen activator (uPA) and coated with a low-fouling peptide that is incorporated within a metal-phenolic network (MPN). The peptide-containing MPN (pep-MPN) coating inhibits the direct contact of uPA with the surrounding environment, as assessed by an in vitro plasminogen activation assay and an ex vivo whole blood clot degradation assay. The pep-MPN-coated cubosomes prepared with 22 wt% peptide demonstrate a cell membrane-dependent thrombolytic activity, which is attributed to their fusogenic lipid behavior. Moreover, compared with the uncoated lipid cubosomes, the uPA-loaded pep-MPN-coated cubosomes demonstrate significantly reduced nonspecific cell association (<10% of the uncoated cubosomes) in the whole blood assay, a prolonged circulating half-life, and reduced splenic uPA accumulation in mice. These studies confirm the preserved bioactivity and cell membrane-dependent release of uPA within pep-MPN-coated lipid cubosomes, highlighting their potential as a delivery vehicle for thrombolytic drugs.
Collapse
Affiliation(s)
- Haitao Yu
- Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria, 3010, Australia
| | - Jason S Palazzolo
- NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Victoria, 3004, Australia
| | - Yi Ju
- Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria, 3010, Australia.,School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, 3083, Australia
| | - Be'eri Niego
- NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Victoria, 3004, Australia
| | - Shuaijun Pan
- Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria, 3010, Australia
| | - Christoph E Hagemeyer
- NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Victoria, 3004, Australia
| | - Frank Caruso
- Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria, 3010, Australia
| |
Collapse
|
6
|
Progress and challenges of lyotropic liquid crystalline nanoparticles for innovative therapies. Int J Pharm 2022; 628:122299. [DOI: 10.1016/j.ijpharm.2022.122299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2022] [Revised: 10/07/2022] [Accepted: 10/10/2022] [Indexed: 11/22/2022]
|
7
|
Potential of curcumin-loaded cubosomes for topical treatment of cervical cancer. J Colloid Interface Sci 2022; 620:419-430. [DOI: 10.1016/j.jcis.2022.04.031] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 03/29/2022] [Accepted: 04/05/2022] [Indexed: 12/14/2022]
|
8
|
Influence of hexadecylphosphocholine (Miltefosine) in phytantriol-based cubosomes: A structural investigation. Colloids Surf A Physicochem Eng Asp 2022. [DOI: 10.1016/j.colsurfa.2021.127720] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|